MAVS Gene Variant Tied to Higher Kaposi Sarcoma Risk in HIV Patients

Genetic Clue in Kaposi Sarcoma Risk

A new study has linked a variant in the MAVS gene to a heightened risk of Kaposi sarcoma in people living with HIV. Kaposi sarcoma is a cancer that causes lesions in the skin, lymph nodes, and other organs, and it remains a significant concern for immunocompromised individuals despite antiretroviral therapy.

The research, reported by EMJ, points to the MAVS gene as a key player in the body's antiviral defence. MAVS helps trigger immune responses against viruses like Kaposi sarcoma-associated herpesvirus (KSHV), which causes the cancer.

How the Gene Variant Works

Scientists found that a specific variation in the MAVS gene impairs its function, weakening the immune system's ability to control KSHV. This allows the virus to replicate more freely, increasing the likelihood of cancerous growths.

People with HIV already face a compromised immune system. The addition of a faulty MAVS gene further reduces their ability to fight off KSHV, creating a double blow that raises cancer risk.

Implications for Screening

The discovery opens the door to genetic screening for HIV patients. Doctors could identify those carrying the MAVS variant early and monitor them more closely for signs of Kaposi sarcoma.

Early detection is crucial. Kaposi sarcoma lesions can be treated effectively when caught in time, but advanced cases are harder to manage. Genetic profiling could help prioritise resources for the most vulnerable patients.

Beyond Kaposi Sarcoma

MAVS is involved in immune responses to other viruses too. The findings may have broader implications for understanding cancer risk in immunocompromised populations, including transplant recipients and people on immunosuppressive drugs.

Researchers are now investigating whether similar gene variants affect susceptibility to other KSHV-related conditions, such as primary effusion lymphoma and multicentric Castleman disease.

While the study is still in its early stages, it provides a clear target for future therapies. Drugs that boost MAVS activity could potentially reduce Kaposi sarcoma risk in carriers of the variant.

Officials have not yet confirmed whether clinical trials are planned, but the research community is watching closely. The next step will be to validate the findings in larger, more diverse populations before any screening programmes are rolled out.